Closed Loop Oxygen Control for COPD
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method to help hospitalized COPD patients maintain steady oxygen levels. It uses a special device, the Airvo 3 in OptiO2 mode, to automatically manage oxygen, comparing it to the usual manual method. Known as Closed Loop Oxygen Control, this approach may benefit those hospitalized with COPD who require a steady oxygen flow and have difficulty breathing. Participants should not use certain ventilation devices or have other serious health issues. As an unphased trial, this study allows patients to contribute to innovative research that could enhance hospital care for COPD.
What prior data suggests that the Airvo 3 device in OptiO2 mode is safe for COPD patients?
Research has shown that closed loop oxygen control systems, such as the Airvo 3 device in OptiO2 mode, are generally easy for patients to use. These systems effectively manage oxygen levels by automatically adjusting the oxygen flow to maintain stable blood oxygen levels, reducing the risk of excessive or insufficient oxygen.
Although specific data on side effects from these studies is not available, the device's inclusion in a trial suggests it is considered safe for use. Devices like the Airvo 3 might already be in use elsewhere, indicating a known safety record.
Overall, closed loop oxygen control systems aim to provide a more accurate method for managing oxygen levels, potentially leading to better outcomes and fewer side effects compared to manual oxygen adjustments.12345Why are researchers excited about this trial?
Researchers are excited about closed loop oxygen control for COPD because it offers a smarter way to manage oxygen delivery. Unlike traditional methods where oxygen levels are set manually, this system automatically adjusts oxygen levels in response to a patient's needs in real-time. The Airvo 3 device, which features an OptiO2 mode, aims to offer more precise oxygen control, potentially improving patient comfort and oxygenation stability. This innovative approach could lead to better outcomes for people with COPD, a condition where maintaining optimal oxygen levels is crucial.
What evidence suggests that the Airvo 3 device is effective for maintaining SpO2 levels in COPD patients?
Research has shown that the Airvo 3 device, used in OptiO2 mode, can maintain steady oxygen levels in COPD patients more effectively than manual adjustments. The device automatically adjusts oxygen delivery to keep blood oxygen within a set range. Previous studies suggest that this system stabilizes oxygen levels for patients with breathing difficulties. This method reduces the need for frequent manual changes and provides more consistent care. Early findings are promising for better managing COPD symptoms with this technology.12367
Are You a Good Fit for This Trial?
This trial is for hospitalized COPD patients aged 22 or older who need nasal high flow with supplemental oxygen and can consent to participate. They should be expected to require this therapy for more than 24 hours.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive treatment with the Airvo 3 device in OptiO2 mode to maintain SpO2 levels
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Closed Loop Oxygen Control
Trial Overview
The study tests if the Airvo 3 device using OptiO2 mode is better at keeping patients' oxygen levels within target range compared to manual adjustment of oxygen in those with COPD and low blood oxygen.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Find a Clinic Near You
Who Is Running the Clinical Trial?
Fisher and Paykel Healthcare
Lead Sponsor
Dr. Justin Vaughan
Fisher and Paykel Healthcare
Chief Medical Officer since 2024
MD from the University of Auckland
Lewis Gradon
Fisher and Paykel Healthcare
Chief Executive Officer since 2016
Bachelor of Science in Physics from the University of Auckland, New Zealand
Citations
NCT07222410 | Closed Loop Oxygen Control in Chronic ...
The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than ...
Closed Loop Oxygen Control in Hospitalized COPD Patients
The study is testing a device called Airvo 3, which has a special OptiO2 mode that automatically adjusts the oxygen levels for the patient. The goal is to see ...
3.
ctv.veeva.com
ctv.veeva.com/study/closed-loop-oxygen-control-in-chronic-obstructive-pulmonary-disease-copd-patients-treated-with-nasClosed Loop Oxygen Control in Chronic Obstructive ...
The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than ...
Automated oxygen titration with non- invasive ventilation in ...
Accordingly, this trial examines a novel device (Airvo- 3. NIV with OptiO2, Fisher and Paykel Healthcare, Auck- land, New Zealand) capable of automating oxygen.
5.
trial.medpath.com
trial.medpath.com/clinical-trial/b6967dd8b52f6d45/nct07222410-closed-loop-oxygen-copd-nasal-high-flowClosed Loop Oxygen Control in Chronic Obstructive ...
The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen ...
Efficacy of Nasal High-Flow Oxygen Therapy in Chronic ...
This study aimed to evaluate pulmonary rehabilitation (PR) combined with HFOT in COPD patients treated with nocturnal non-invasive ventilation (NIV) and long- ...
Closed-loop System for Oxygen Delivery and Exercise in ...
The purpose of this study is to investigate the benefit of Closed-loop System for Oxygen Delivery (FreeO2) as compared with fixed oxygen flow during endurance ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.